

Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors†

Cite this: *Med. Chem. Commun.*, 2013, **4**, 1305

James S. Scott,^{*a} David J. Berry,^b Hayley S. Brown,^a Linda Buckett,^a David S. Clarke,^a Kristin Goldberg,^a Julian A. Hudson,^a Andrew G. Leach,^a Philip A. MacFaul,^a Piotr Raubo^a and Graeme Robb^a

Received 4th June 2013
Accepted 29th July 2013

DOI: 10.1039/c3md00156c

www.rsc.org/medchemcomm

Monoacylglycerolacetyltransferase-2 (MGAT2) is a potential target for the treatment of type II diabetes. We report here the optimisation of a series of MGAT2 inhibitors with regard to their potency and permeability. Improvements in permeability, as measured by increased flux in a Caco-2 assay, were achieved through substitution at the 9-position of the core. We propose that reduction of the NH hydrogen-bond donor strength was primarily responsible for these effects.

Monoacylglycerolacetyltransferase-2 (MGAT2) is a member of the family of enzymes that catalyses the synthesis of diacylglycerol from monoacylglycerol and fatty acyl CoA.¹ It is located in the endoplasmic reticulum and is highly expressed in the small intestine.² Preclinical studies have shown that MGAT2 deficient mice show resistance to obesity, hyperglycaemia, hypercholesterolaemia and hepatic steatosis induced by a high fat diet.³ Increased energy expenditure, even in the absence of a high fat diet, is at least partly responsible for these protective effects.⁴ Inhibition of MGAT2 has therefore attracted interest as a potential mechanism for treatment of the metabolic syndrome. We have recently reported a novel series of MGAT2 inhibitors⁵ and herein report further optimization, primarily focused on increasing the membrane permeability of the compounds.

Membrane permeability is a key consideration in drug discovery, particularly in the *in vivo* absorption of oral drugs and the ability of molecules to access intracellular targets. In general, within a chemical series, the permeability decreases with increasing polarity although other factors, such as molecular weight, are important.⁶ In recent years, the strategy of keeping lipophilicity of drug candidates low has been highlighted as a way of increasing the likelihood of achieving soluble compounds that are metabolically stable and avoid potential toxicological risks.⁷ One of the consequences of working in low lipophilicity space however, is that permeability is more likely to become an issue.

Systematic methylation of the three hydrogen bond donors present in our series of MGAT2 inhibitors had been previously

examined.⁵ This had resulted in improvements in permeability, as assessed in a Caco-2 assay (apical pH = 6.5; basolateral pH = 7.4).⁸ This was consistent with a reduction in hydrogen bond donor count, but had led to an unacceptable loss in potency for the three molecular matched pairs (Fig. 1). Notably, methylation of R4 appeared to have the least impact on Caco-2 permeability, with more significant changes being observed at R1 and R7. In attempts to achieve potent yet permeable compounds, we sought to retain the three donors but to modulate their strength by electronic and steric effects through substitution of the core aryl ring.^{9–12}

Results from aryl ring substitution of the core are shown in Table 1. In the case of fluoro substitution (2–4), the 6-fluoro resulted in a large drop in potency whereas substitution in the 8- or 9-positions resulted in less than a two-fold change. In terms of permeability, the 6- and 8-substitutions resulted in no change, however, 9-substitution, proximal to the amide NH, did result in increased permeability. In the case of methoxy substituents (5–7), substitution at the 6-position was not tolerated with 8-substitution also resulting in a drop in potency. By contrast, 9-substitution resulted in an increase in both potency and permeability. Methyl substitution (8–10) showed similar SAR in terms of potency, with 6- and 8-substitution resulting in lower potencies relative to the un-substituted core. As before, 9-substitution resulted in increased potency and an improvement in terms of Ligand Lipophilicity Efficiency (LLE)¹³ of +1.3 relative to the un-substituted core. In terms of permeability, for all three methyl isomers, the data was very similar to the un-substituted core with no improvement observed, even at the 9-position. The pyridyl analogues (11, 12) were also examined. In the case of the 8-pyridyl compound the potency was lowered, however, this was accompanied by an expected drop in lipophilicity with the value for LLE remaining the same as the phenyl matched pair. Here the permeability was measured to be lower as may be expected based on a lower lipophilicity compound. The 9-pyridyl compound lost a greater degree of

^aAstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. E-mail: jamie.scott@astrazeneca.com; Fax: +44 (0)1625 516667; Tel: +44 (0)1625 232567

^bDurham University, School of Medicine, Pharmacy and Health, Wolfson Research Institute, Queen's Campus, Stockton on Tees, TS17 6BH, UK

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c3md00156c




Fig. 1 Effect of methylation on MGAT2 potency and permeability.

Table 1 Human MGAT2 potencies, lipophilicity and permeability data for core substitution

Cpd	Substitution	MGAT2 IC ₅₀ ^a	Log D _{7.4}	LLE (pIC ₅₀ – log D)	Caco-2 A-B P _{app} (x10 ⁻⁶ cm s ⁻¹)
1	H	0.911	2.6	3.4	6
2	6-F	40.4	2.4	2.0	4
3	8-F	1.49	2.3	3.5	5
4	9-F	1.95	2.3	3.4	14
5	6-OMe	>100	1.9	—	7
6	8-OMe	7.61	2.8	2.3	1
7	9-OMe	0.109	2.6	4.4	12
8	6-Me	13.6	—	—	9
9	8-Me	13.4	3.0	1.9	7
10	9-Me	0.052	2.6	4.7	7
11	8-azaN	10.5	1.6	3.4	1
12	9-azaN	>66	1.8	—	10

^a IC₅₀ value from the human MGAT2 Rapidfire LCMS® assay.

potency than would be expected from lipophilicity alone. Interestingly however, it showed a surprising increase in permeability relative to the isolipophilic 8-pyridyl isomer and retained similar permeability when compared to the more lipophilic aryl core. Our conclusion from these data was that modulation of the 9-position offered an opportunity to increase permeability (F, OMe, aza-N) and potency (Me, OMe) with methoxy offering an opportunity to do both simultaneously.

Exploration of the R9 substituent (Table 2) was carried out contemporaneously in a 2,4-fluoro aniline series which had been previously shown⁵ to be considerably more potent and less lipophilic than the 4-trifluoromethyl aniline (contrast matched pair **1** and **13**). Methyl substitution resulted in an increase in potency although this was less dramatic than seen previously (Δ LLE for **10** and **1** = +1.3; Δ LLE for **14** and **13** = +0.5). Cyano substitution **15** resulted in lower potency and permeability. Trifluoromethyl **16** retained potency and provided a dramatic enhancement in permeability.

The effect of 9-substitution was also examined in a series with racemic methyl, ethyl (as opposed to methyl, methyl)

Table 2 Human MGAT2 potencies, lipophilicity and permeability data for R9 substitution

Cpd	R9 substitution	MGAT2 IC ₅₀ ^a	Log D _{7.4}	LLE (pIC ₅₀ – log D)	Caco-2 A-B P _{app} (x10 ⁻⁶ cm s ⁻¹)
13	H	0.058	1.3	5.9	5
14	Me	0.016	1.4	6.4	10
15	CN	0.405	—	—	3
16	CF ₃	0.030	1.9	5.6	46

^a IC₅₀ value from the human MGAT2 Rapidfire LCMS® assay.

substitution of the bis-amide ring (Table 3). Here the potency enhancements seen with 9-substitution were less marked with all substituents examined (OMe, Et, Cl) showing similar values of LLE to the un-substituted compound **17**. In terms of permeability, an enhancement was seen for all 9-substituted

Table 3 Human MGAT2 potencies, lipophilicity and permeability data for R9 substitution

Cpd	R9 substitution	MGAT2 IC ₅₀ ^a	Log D _{7.4}	LLE (pIC ₅₀ – log D)	Caco-2 A-B P _{app} (x10 ⁻⁶ cm s ⁻¹)
17 ^b	H	0.010	1.7	6.2	8
18	OMe	0.010	1.8	6.2	22
19	Et	0.004	2.1	6.3	24
20	Cl	0.009	1.9	6.1	35
21a ^c	Me	0.007	1.7	6.5	9
21b ^c	Me	0.062	1.8	5.4	14


^a IC₅₀ value from the human MGAT2 Rapidfire LCMS® assay.

^b Compound is the enantiomerically pure (*S*)-isomer. ^c Compounds are enantiomerically pure but the absolute stereochemistry is unknown.

compounds, notably so for the chloro compound **20**. In the case of the methyl substituted compounds, these were synthesised in enantiomerically pure form based on the separation of an intermediate by chiral HPLC. Isomer **21a** (absolute stereochemistry undetermined) was approximately nine-fold more potent than enantiomeric **21b** resulting in a high value for LLE (6.5). In common with the data presented in Tables 1 and 2, methyl substitution offered little to no enhancement of permeability.

With the chloro substituent offering the largest improvements in terms of permeability,¹⁴ this was examined in conjunction with other sulphonamide substituents (Table 4).¹⁵

Table 4 Human MGAT2 potencies, lipophilicity and permeability data for combinations




Cpd	R9 substitution	R aryl substitution	MGAT2 IC ₅₀ ^a	Log D _{7,4}	LLE (pIC ₅₀ - log D)	Caco-2 A-B P _{app} (×10 ⁻⁶ cm s ⁻¹)
22^b	H	2F,4CF ₃	0.012	1.9	6.0	9
23	Cl	2F,4CF ₃	0.012	2.2	5.7	29
24	Cl	2OMe,4CF ₃	0.007	3.0	5.2	58
25a^c	Cl	2CN,4Me	0.023	0.4	7.2	14
25b^c	Cl	2CN,4Me	0.117	0.6	6.3	11

^a IC₅₀ value from the human MGAT2 Rapidfire LCMS® assay.

^b Compound is the enantiomerically pure (*S*)-isomer. ^c Compounds are enantiomerically pure but the absolute stereochemistry is unknown.

Comparison of the 2-fluoro-4-trifluoromethyl sulphonamide pair **22** and **23** with and without a 9-chloro substituent shows an approximate three-fold increase in permeability for the chloro substituted compound **23**. In the case of the 2-methoxy-4-trifluoromethyl sulphonamide **24** an increase in lipophilicity was observed together with a further increase in permeability. This compound had the highest Caco-2 value (P_{app} 58 × 10⁻⁶ cm s⁻¹) of any member in the series together with high potency (IC₅₀ 7 nM). Interestingly, even low lipophilicity compounds containing the 2-cyano-4-methyl sulphonamide (**25**) retained reasonable Caco-2 values (>10 × 10⁻⁶ cm s⁻¹) despite low

Table 5 Log *k_x* and Log *k_β* values for 9-substituted compounds



Entry	9-Substituent	Log <i>k_β</i> A	Log <i>k_x</i> B	Log <i>k_β</i> C	Log <i>k_x</i> D
1	H	2.12/2.12	0.35	1.37/1.38	0.98
2	Me	2.22/2.28	0.31	1.44/1.43	0.88
3	Et	2.25/2.32	0.30	1.48/1.46	0.86
4	Cl	1.88/1.89	0.57	1.22/1.31	0.71
5	CF ₃	1.78/1.74	0.68	1.26/1.15	0.83
6	CN	1.45/1.54	0.84	1.08/0.92	1.06




Fig. 2 Plots of permeability against log *D*_{7,4} (A) and MGAT2 potency against permeability (B), grouped by 9-substituent and shaped by 9-substituent.




Fig. 3 Bivariate plot of Caco-2 P_{app} (log scale) and $\log k_a$ (D) showing a correlation between the two. Open, blue points are from Table 2; closed, green points are from Table 3. $R^2 = 0.77$; RMSE = 0.46; probability of such a relationship happening by chance is 0.0018.

$\log D_{7.4}$ values (~ 0.5). As in the case of compound **21**, a clear difference in potency between the separated enantiomers was observed.

A graphical overview of the full dataset for this series is shown in Fig. 2, of which the compounds described in this paper are a subset. Fig. 2A shows permeability plotted against measured $\log D_{7.4}$ and trellised according to the 9-substitution

pattern. A dashed line showing the value of Caco-2 A-B $P_{app} = 10 \times 10^{-6} \text{ cm s}^{-1}$ has been added to aid visual comparison. For the compounds with no substitution at the 9-position, only 2/41 (5%) has a P_{app} value $> 10 \times 10^{-6} \text{ cm s}^{-1}$. For the 9-methyl set, 12/47 (26%) have a P_{app} value $> 10 \times 10^{-6} \text{ cm s}^{-1}$ and when only compounds with a $\log D_{7.4} > 1.5$ are considered, this proportion increases to 12/25 (48%). All of the 15 compounds with a methoxy, ethyl or chloro substituent show P_{app} value $> 10 \times 10^{-6} \text{ cm s}^{-1}$, even for those chloro substituted compounds with low lipophilicity ($\log D_{7.4} 0.5$). Fig. 2B shows MGAT2 potency plotted against permeability with a target area ($\text{pIC}_{50} > 8$; $P_{app} > 10 \times 10^{-6} \text{ cm s}^{-1}$ shaded in grey). For the un-substituted series only one compound of the set of 54 satisfy this criteria. For the 9-methyl compounds, 4/44 (10%) are both potent and permeable. When the 9-OMe/Et/Cl set are considered, 8/15 (53%) achieve the target, highlighting the importance of 9-substitution in achieving potent and permeable compounds in this series.

In an attempt to understand the influence of the 9-substituent on the electronics of the core, the strength of hydrogen-bond donors ($\log k_a$) and hydrogen-bond acceptors ($\log k_b$) labelled A–D were calculated using quantum mechanics (Gaussian 09 using B3LYP functional and 6-31G* basis set)¹⁶. The labelling and values for the 9-methyl substituted core is shown in Table 5. Each of the carbonyls has two values corresponding to the orbital lobes on the oxygen lone pairs. These




Fig. 4 (a) Strong H-bonding interactions in **26**. These bonds support a chain structure down the b -axis. (b) **26** viewed down the b -axis (c) **27** viewed down the b -axis (d) **28** viewed down the b -axis.

calculations account for both through-bond and through-space electronic effects of the 9-substituent.

The calculated hydrogen-bond donor and acceptor strengths for a range of 9-substituents corresponding to the compounds from Tables 2 and 3 are shown in Table 5. These compounds have fixed aryl substitution (2,4-difluoro) and differ only in the substitution of the bis-amide ring (where ethyl or methyl substitution result in equivalent permeability). Simple bivariate statistics were used to elucidate any relationships between Caco-2 P_{app} and calculated hydrogen-bond strength (Caco-2 P_{app} values

have been put on a log-scale so as to be normally distributed). The relationship with the strength of the adjacent hydrogen-bond donor (D) clearly shows a strong correlation with log Caco-2 P_{app} as shown in Fig. 3. The probability (P) of this correlation arising by chance is 0.0018, whilst for all other calculated hydrogen-bond strengths $P \geq 0.5$. The correlation of permeability with log k_a (D) is also better than for log $D_{7,4}$ ($P = 0.024$). This result helps rationalize the observed permeability: Higher permeability is associated with lower hydrogen-bond donor strength (Cl, CF_3), and low permeability is associated with higher hydrogen-bond donor strength (H, CN).

In order to understand any effects on the solid state of these compounds, small molecule X-ray crystal structures were obtained of several members of this series. Although there are differences in symmetry and packing density across the unsubstituted compounds (26–28), similar packing motifs around a strong H-bonded chain between the amides of the cores with a sulphonamide backbone are consistently observed in all three structures (Fig. 4). In the 9-chloro analogue (23), similar amide interactions between the cores are retained, however, it is noteworthy that the sulphonamide H-bonding motifs are completely absent in this structure (Fig. 5).

Compounds were synthesized using a modified version of the previously described route⁵ whereby cyclisations were carried out on the amino ester intermediates of type 29 (Scheme 1). This circumvented difficulties associated with isolation of the previously employed amino acids. The amino esters were synthesized from amide coupling of 2-amino benzoic acids 30, regioselective ring opening of isatoic anhydrides 31 or amide coupling of 2-nitro benzoic acids 32 followed by reduction of the nitro group 33. Cyclisation to form the core 34 was carried out using acidic conditions and the various substitutions (R6, R8, R9) were generally well tolerated with the exception of (R6 = F) which proceeded in low yield (8%). Acetic acid was initially used in the cyclisation, however, it was noted that acetylation of the aniline was a significant by-product in some cases. This problem was overcome by switching to the more sterically hindered pivalic acid resulting in cleaner reaction profiles and higher isolated yields. Treatment with chlorosulphonic acid generated the corresponding sulphonyl chlorides 35 with






Fig. 5 (a) Strong H-bonding interactions in 23. These bonds support a chain structure down the b -axis with weaker interactions supporting layering down the a -axis. This is viewed along an intersection of the b/c -axis. (b) 23 packing down a -axis.



Scheme 1 General synthetic approaches. *Reagents:* (a) $\text{H}_2\text{NCR}_3(\text{Me})\text{COOMe}$, HATU, $(i\text{-Pr})_2\text{NEt}$, DMF, 76–100%; (b) $\text{H}_2\text{NCR}_3(\text{Me})\text{COOMe}$, $(i\text{-Pr})_2\text{NEt}$, DMF, 60 °C, 55–70%; (c) H_2 , Pd/C, EtOH, 93–100%; (d) MeCOOH or $t\text{BuCOOH}$, μW , 180–200 °C, 8–99%; (e) ClSO_3H , 65–90 °C, 32–100%; (f) ArNH_2 , pyridine, CH_2Cl_2 , 25–100 °C, 13–88%; (g) $\text{Pd}_2(\text{dba})_3$, XPhos, Zn, $\text{Zn}(\text{CN})_2$, DMA, μW , 120 °C, 2 h, 82%.



Scheme 2 Synthesis of aza-analogues **11** & **12**. Reagents: (a) $\text{H}_2\text{N}(\text{Me}_2)\text{COOMe}$, HATU, $(^i\text{Pr})_2\text{NEt}$, DMF, 20°C , 45 min, 90%; (b) TFA, CH_2Cl_2 , 20°C , 3 h, 100%; (c) $^t\text{BuCOOH}$, μW , 200°C , 3 h, 35%; (d) BnSH , $^t\text{BuOK}$, DMF, 80°C , 3 h, 94%; (e) (i) NCS, AcOH, H_2O , 20°C , 10 min; (ii) $4\text{-CF}_3\text{C}_6\text{H}_4\text{NH}_2$, pyridine, 20°C , 3 h, 22%; (f) ClSO_3H , 65°C , 18 h; (g) $4\text{-CF}_3\text{C}_6\text{H}_4\text{NH}_2$, pyridine, 20°C , 3 days, 9% over 2 steps; (h) $\text{H}_2\text{N}(\text{Me}_2)\text{COOMe}$, HATU, $(^i\text{Pr})_2\text{NEt}$, DMF, 20°C , 18 h, 29%; (i) $^t\text{BuCOOH}$, 200°C , 28 h, 56%.

excellent regioselectivity for the 7-position regardless of core substitution (R_6 , R_8 , R_9) in all cases (presumably directed by the aniline amide N_1). In the case of $\text{R}_9 = \text{CN}$, this compound was made from the fully elaborated sulphonamide with $\text{R}_9 = \text{Br}$ and subjected to palladium catalysed cyanation conditions giving compound **15** in good yield.

The enantiomerically pure compounds **17** and **22** ($\text{R}_9 = \text{H}$) were obtained by chiral HPLC separation of the cyclised core prior to sulphonylation. Treatment with chlorosulphonic acid and sulphonamide coupling gave the desired products with the absolute configuration being identified as (*3S*) based on X-ray crystallography. Compounds **21a** and **21b** ($\text{R}_9 = \text{H}$) were made in a similar fashion although the absolute configuration was not determined. In the case of compounds **25a** and **25b** these were made by chiral separation of racemic **25** and the absolute configuration was not determined.

For the aza-analogues it was found that the sulphonylations would not occur on the fully elaborated core (presumably due to the electron deficiency of the pyridyl ring) and so these were made according to the procedures outlined in Scheme 2. For the 8-aza compound **11**, the core was constructed from the 2-chloropyridine **36** via amide coupling, Boc deprotection to aniline **38** and cyclisation using pivalic acid to the 8-aza core **39**. The chloro substituent was then displaced with a benzylthiol to give **40** and then oxidized to a sulphonyl chloride and quenched with 4-trifluoromethyl aniline to generate sulphonamide **11**. For the 9-aza compound **12**, an alternative approach was utilized whereby the 2-anilinopyridine **41** was regioselectively converted to the sulphonyl chloride **42** and then coupled in low yield to form the sulphonamide **43**. Amide coupling to form anilinoester **44** and cyclisation under pivalic acid conditions gave sulphonamide **12**.

As a representative example of this series, compound **20** was profiled further (Table 6). The compound showed no significant inhibition against four isoforms of the cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2D6 and CYP3A4 all $\text{IC}_{50} > 30 \mu\text{M}$) and only weak activity against CYP2C19 ($\text{IC}_{50} 27 \mu\text{M}$). No inhibition of the hERG ion channel ($\text{IC}_{50} > 100 \mu\text{M}$) was observed. Plasma protein binding showed reasonable free levels (1.7–3.7% free across species) in line with the low lipophilicity of the compound ($\log D_{7.4} 1.9$). The measured pK_a of the

Table 6 Physical properties of compound **20**

Aqueous solubility ^a (μM)	Mouse PPB ^b (% free)	Rat PPB ^b (% free)	Human PPB ^b (% free)	hERG IC_{50} ^c (μM)
150	3.7	3.0	1.7	>100

^a Solubility of compounds in aqueous phosphate buffer at pH 7.4 after 24 hours at 25°C (μM). ^b PPB was assessed by equilibrium dialysis in the appropriate species plasma at 37°C . Free and bound concentrations were quantified by LC-UVMS. ^c Inhibition of hERG channel IC_{50} (μM) in a electrophysiology (IonWorksTM) assay.

Table 7 Pharmacokinetic parameters for selected compound **20**^a

Species	Clp ($\text{mL min}^{-1} \text{kg}^{-1}$)	Vd_{ss} (L kg^{-1})	IV half-life (h)	Oral half-life (h)	Bioavailability (%)
Mouse	29	0.5	0.2	1.2	74
Rat	4.1	0.4	1.3	2.4	69

^a Dosed PO at 3 mg kg^{-1} (rat) and 50 mg kg^{-1} (mouse) in suspension (HPMC/Tween) and IV (1 mg kg^{-1}) in 5% DMSO: 95% hydroxypropyl β cyclodextrin. Data is mean of two animals in a single experiment.

sulphonamide NH was 5.9. The aqueous solubility as measured on crystalline material was $150 \mu\text{M}$.

The oral pharmacokinetic profile of compound **20** was examined in rat at low dose (3 mg kg^{-1}) and mouse at high dose (50 mg kg^{-1}) with the results are summarised in Table 7. From IV data the compound showed moderate clearance in mouse and low clearance in rat together with a low volume of distribution in both species. Good bioavailabilities (>60%) were observed in both species.

Conclusion

In summary we have reported the optimization of a series of MGAT2 inhibitors to give potent compounds such as **20** that have favourable physical and pharmacokinetic properties. In particular the permeability, as measured by increased flux in a Caco-2 assay, has been improved through substitution at the 9-position of the core. This was achieved without recourse to

increasing the lipophilicity of the compounds but rather through modulation of the hydrogen bond donor strength of an amide NH.

Acknowledgements

Scott Boyd, Ben Chappell, Paul Kemmitt and Paul Schofield are thanked for synthetic contributions. Michael Tonge is acknowledged for generating enzyme inhibition data. Per Svensson and Anne Ertan are thanked for crystallography contributions. We also thank Nicholas Newcombe and Andrew Turnbull for project leadership.

References

- 1 C.-L. E. Yen and R. V. Farese Jr, *J. Biol. Chem.*, 2003, **278**, 18532.
- 2 R. M. Bell and R. A. Coleman, *Annu. Rev. Biochem.*, 1980, **49**, 459.
- 3 C.-L. E. Yen, M.-L. Cheong, C. Grueter, P. Zhou, J. Moriwaki, J. S. Wong, B. Hubbard, S. Mamour and R. V. Farese Jr, *Nat. Med.*, 2009, **15**, 442.
- 4 D. W. Nelson, Y. Gao, N. M. Spencer, T. Banh and C.-L. E. Yen, *J. Lipid Res.*, 2011, **52**, 1723.
- 5 J. G. Barlind, L. K. Buckett, S. G. Crosby, Ö. Davidsson, H. Emtenä, A. Ertan, U. Jurva, M. Lemurell, K. Nilsson, G. O'Mahony, A. U. Petersson, A. Redzic, F. Wågberg and Z.-Q. Yuan, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 2721.
- 6 M. J. Waring, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 2844.
- 7 M. J. Waring, *Expert Opin. Drug Discovery*, 2010, **5**, 235.
- 8 R. Hayeshia, C. Hilgendorf, P. Artursson, P. Augustijns, B. Brodin, P. Dehertogh, K. Fisher, L. Fossati, E. Hovenkamp, T. Korjamo, C. Masungi, N. Maubon, R. Mols, A. Müllertz, J. Mönkkönen, C. O'Driscoll, H. M. Oppers-Tiemissen, E. G. B. Ragnarsson, M. Rooseboom and A.-L. Ungell, *Eur. J. Pharm. Sci.*, 2008, **35**, 383.
- 9 Increasing permeability through alteration of hydrogen bond strength through addition of proximal groups has been described in the literature. For a recent review see P. V. Desai, T. J. Raub and M.-J. Blanco, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 6540.
- 10 C. D. Cox, M. J. Breslin, D. B. Whitman, P. J. Coleman, R. M. Garbaccio, M. E. Fraley, M. M. Zrada, C. A. Buser, E. S. Walsh, K. Hamilton, R. B. Lobell, W. Tao, M. T. Abrams, V. J. South, H. E. Huber, N. E. Kohl and G. D. Hartman, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 2697.
- 11 J. F. Levesque, K. Bleasby, A. Chefson, A. Chen, D. Dube, Y. Ducharme, P. A. Fournier, S. Gagne, M. Gallant, E. Grimm, M. Hafey, Y. Han, R. Houle, P. Lacombe, S. Laliberte, D. MacDonald, B. Mackay, R. Papp and R. Tschirret-Guth, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 5547.
- 12 S. B. Rafi, B. R. Hearn, P. Vedantham, M. P. Jacobson and A. R. Renslo, *J. Med. Chem.*, 2012, **55**, 3163.
- 13 P. D. Leeson and B. Springthorpe, *Nat. Rev. Drug Discovery*, 2007, **6**, 881.
- 14 Other groups such as 9-F (Table 1) and 9-CF₃ (Table 2) showed permeability increases in other sets of matched pairs but were viewed on balance as being less optimal than the Cl. In the case of the F, the permeability rise was less pronounced and the CF₃ added both lipophilicity and molecular weight. The exact matched pairs with 9-Cl were not made as part of this program of work.
- 15 Structure-activity-relationship information from sulphonamide library work revealed that 2,4-disubstitution was a preferred motif in this series and that electron withdrawing substituents (particularly in the 2-position) were favourable for potency.
- 16 (a) P. Kenny, *J. Chem. Inf. Model.*, 2009, **49**, 1234; (b) P. W. Kenny, *J. Chem. Soc., Perkin Trans. 2*, 1994, 199.